Key Facts Surrounding This News Item
- ALLO had returned 0.00% year-to-date leading up to today’s news, versus a +9.11% return from the benchmark S&P 500 during the same period.
More Info About Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is based in South San Francisco, California. View our full ALLO ticker page with ratings, news, and more.